Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,044,235
  • Shares Outstanding, K 89,788
  • Annual Sales, $ 0 K
  • Annual Income, $ -273,550 K
  • 60-Month Beta 2.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.79
  • Number of Estimates 4
  • High Estimate -0.71
  • Low Estimate -0.86
  • Prior Year -1.07
  • Growth Rate Est. (year over year) +26.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.16 +6.54%
on 02/14/20
14.40 -17.43%
on 02/10/20
-1.99 (-14.34%)
since 01/17/20
3-Month
11.16 +6.54%
on 02/14/20
19.58 -39.27%
on 12/03/19
-1.03 (-7.97%)
since 11/19/19
52-Week
4.14 +187.20%
on 10/29/19
26.02 -54.30%
on 04/03/19
-9.35 (-44.02%)
since 02/19/19

Most Recent Stories

More News
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020

MYOV : 11.89 (+2.24%)
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

-- Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss

MYOV : 11.89 (+2.24%)
Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant's CEO, will present...

JPM : 136.50 (+0.63%)
MYOV : 11.89 (+2.24%)
Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

-- Hiroshi Nomura, President, CEO, and Representative Director of Sumitomo Dainippon Pharma and Adele Gulfo, Chief Business and Commercial Development Officer of Sumitovant Biopharma, appointed to Board...

MYOV : 11.89 (+2.24%)
HTGC : 15.28 (+0.13%)
Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance

Sumitovant Biopharma Ltd. was today unveiled as a new, global biopharmaceutical company through the closing of the transaction previously announced on October 31, 2019 between Sumitomo Dainippon Pharma...

MYOV : 11.89 (+2.24%)
DNPUF : 16.9000 (-0.29%)
Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

CNCR : 22.34 (-0.25%)
BBC : 38.23 (+0.84%)
BBP : 44.92 (+0.40%)
GBT : 71.16 (+0.61%)
PTI : 1.70 (-0.58%)
VRTX : 246.51 (+0.24%)
CLVS : 9.38 (+1.30%)
MYOV : 11.89 (+2.24%)
CNST : 37.70 (+4.55%)
KRTX : 102.49 (+2.78%)
CRSP : 55.34 (-0.63%)
ARKG : 36.96 (+0.27%)
GNOM : 15.92 (-0.31%)
Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?

Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

MYOV : 11.89 (+2.24%)
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant's President and CEO,...

MYOV : 11.89 (+2.24%)
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

CELG : 108.24 (+0.10%)
VRTX : 246.51 (+0.24%)
ALKS : 17.61 (-0.90%)
VTGN : 0.66 (+1.55%)
MYOV : 11.89 (+2.24%)
KRTX : 102.49 (+2.78%)
CRSP : 55.34 (-0.63%)
Why the Global Pain Management Drug Market is Adopting More Non-Opioid Options

It appears that the reign of the opioid drugs in the global pain management markets could be coming to an end. While opioids have long been the 'best' choice to address the pain patients suffer from various...

QBIO : 2.9900 (+19.00%)
MYOV : 11.89 (+2.24%)
HRTX : 21.14 (+0.64%)
BCRX : 2.92 (unch)
ENDP : 5.95 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MYOV with:

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

2nd Resistance Point 12.06
1st Resistance Point 11.84
Last Price 11.89
1st Support Level 11.31
2nd Support Level 11.00

See More

52-Week High 26.02
Fibonacci 61.8% 17.66
Fibonacci 50% 15.08
Fibonacci 38.2% 12.50
Last Price 11.89
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar